A new Alzheimer’s drug, once worth billions, is headed for the trash
Axovant Sciences, 2017's most talked-about biotech company, is abandoning the Alzheimer's drug that made it famous after yet another clinical trial failure.
Axovant Sciences (AXON), 2017’s most talked-about biotech company, is abandoning the drug that made it famous after yet another clinical trial failure.
The company, valued at more than $2.8 billion, a memory-destroying disease that can affect mood and balance. Last year, in a 1,300-patient Alzheimer’s disease trial, sending Axovant’s share price down more than 75 percent.
